Delfi Diagnostics, founded with a mission to revolutionize cancer detection and prevention, focuses on developing high-performing, accessible blood tests for early cancer detection. Leveraging novel machine learning algorithms, Delfi's technology analyzes fragments of cell-free DNA to identify cancer from a single blood sample. Their flagship clinical trial, CASCADE-LUNG, aims to enroll approximately 15,000 participants, underscoring their commitment to scalable and accurate cancer screening solutions.
Notable figures associated with Delfi Diagnostics include Dr. Velculescu, an internationally recognized expert in genomics and cancer research, known for pioneering genome-wide sequence analysis in human cancers. Delfi's team comprises leading experts in cancer biology, bioinformatics, machine learning, and public health. The company's innovative approach has the potential to significantly impact early cancer detection, offering a more comprehensive and accessible screening method compared to existing technologies.
